Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Thyroid Cancer Diagnosis and Treatment, Thyroid and Parathyroid Surgery, Adrenal and Paraganglionic Tumors, and Neuroendocrine Tumor Research Advances.
Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.
Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma.
Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.
Supplementary Table S1 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid with molecular profiling and unusual immunoprofile: a case report
Supplementary Figure S3 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Table S3 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Table S4 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Figure S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Table S7 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Table S6 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Figure S1 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Table S5 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Supplementary Table S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and <sup>131</sup>I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study.
Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
A Score to Predict the Clinical Usefulness of Therapeutic Drug Monitoring: Application to Oral Molecular Targeted Therapies in Cancer.
Management of Pain Medication in Patients With a History of Bariatric Surgery: A Systematic Review.
Gadolinium-based nanoparticles AGuIX and their combination with ionizing radiation trigger AMPK-dependent proinflammatory reprogramming of tumor-associated macrophages
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.
Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Langerhans cell histiocytosis of the suprasellar region: diagnosis based on thyroid cytology.
Supplementary Table S6 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Supplementary Figure S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Supplementary Table S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Supplementary Table S5 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Supplementary Table S3 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer